Every 10-Q that Xenetic Biosciences, Inc. (XBIO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow XBIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XBIO filings page.
Xenetic Biosciences, Inc., a pre-commercial biopharmaceutical company developing DNase-based immune-oncology therapies for difficult-to-treat solid tumors, reported Q2 2026 royalty revenue of $660,601, all from its PolyXen sublicense with Takeda. Six‑month 2026 revenue was $1,467,524, a 24.0% increase over the prior‑year period.
The company recorded a Q2 2026 net loss of $929,695 and a six‑month 2026 net loss of $1,386,077, compared with a loss of $1,591,844 in the first half of 2025. Operating expenses for the first half totaled $2,941,331, with research and development of $1,213,456 and general and administrative of $1,727,875, the latter rising mainly from legal costs tied to a strategic review.
As of June 30, 2026, Xenetic held $6,471,766 in cash, total assets of $6,967,998, current liabilities of $894,977 and working capital of approximately $5.8 million. Management believes existing resources will fund operations for at least twelve months, but additional long‑term capital will be required. All Series B preferred shares were converted into roughly 45,000 common shares, leaving no preferred outstanding and only about 800 warrants. The board is conducting a formal strategic review that may include a sale, asset sale or reverse merger, with no assurance any transaction will occur.
Xenetic Biosciences, Inc. reported a smaller net loss for the quarter ended March 31, 2026 as royalty revenue increased. Royalty revenue rose to $806,923 from $593,261, while net loss narrowed to $456,382 from $903,141.
Operating expenses declined, with research and development and general and administrative costs both slightly lower than a year earlier. Cash was $7.3M and current liabilities about $1.0M, and the company believes existing resources can fund operations for at least twelve months, though additional capital will be needed longer term.
The company is conducting a formal strategic review, considering options including a sale, asset sale, or reverse merger that could leave counterparties’ investors holding a substantial majority of common stock. Xenetic continues to focus on advancing its DNase immuno-oncology technology and relies primarily on equity funding and royalties from its PolyXen license.
Xenetic Biosciences (XBIO) filed its Q3 2025 10‑Q, reporting royalty-driven revenue of $1,026,957 and a net loss of $509,940 (basic and diluted loss per share $0.33). Royalties stem from a sublicense with Takeda and rose versus last year.
Operating expenses included R&D $756,482 and G&A $815,209. Cash was $4,121,599 and total current liabilities were $1,111,775 as of September 30, 2025, reflecting continued focus on DNase research. Management believes existing resources fund operations for at least twelve months from issuance.
After quarter-end, the company completed an underwritten offering of 735,000 common shares at $6.12 per share, with estimated net proceeds of ~$3.9 million. Xenetic and its board began a strategic review considering alternatives, including a potential business combination or sale; the process has no set timetable and outcomes are uncertain. Common shares outstanding were 2,291,056 as of November 7, 2025.
Xenetic Biosciences reported a narrowing net loss driven by lower operating expenses while continuing to receive royalties from Takeda. Royalty revenue was $589,897 for the quarter and $1,183,158 for the six months ended June 30, 2025. The company recorded a net loss of $688,703 for the quarter and $1,591,844 for the six-month period. Cash totaled $4,779,846 at June 30, 2025 and working capital was approximately $4.5 million, while total assets were $5.35 million.
Operating costs fell year-over-year as R&D and general and administrative expenses declined, largely reflecting lower personnel and severance-related items recognized in 2024. Management states existing resources are adequate to fund operations for at least twelve months from issuance of these financial statements, but the company anticipates the need for additional capital longer term to advance its DNase clinical program and other initiatives.